MediGear

Amazing Gut | Pelvic Floor Biofeedback and Home Therapy

Wed, 13 May 2026 16:53:01 +0800

Company Profile

Amazing Gut Pty Ltd is an Australia-based developer of home-use pelvic floor biofeedback devices, headquartered in Sydney, NSW 2088, Australia. Founded in April 2025 by Dr Jerry Zhou and A/Prof Vincent Ho as a Western Sydney University spin-out, the company operates as an independent privately-held entity with a small founding team, serving patients with bowel disorders and healthcare providers in Australia with planned global expansion.

Core Products and Technologies

Home Biofeedback Systems

• Ins＆Outs: Wireless home-use pelvic floor exercise biofeedback device with smart sensors and real-time app-guided muscle training for chronic constipation, faecal incontinence and rectal pain/spasms
• Companion App: Android and iOS interface with visual biofeedback, programmable exercises and remote clinician monitoring
• Cloud Monitoring: Data sharing with therapists for remote progress tracking and treatment refinement

Platform Technology

• Smart Sensors: High-sensitivity pressure sensors for simultaneous anal sphincter and rectal pressure measurement
• IoT Connectivity: Wireless data transmission enabling remote clinician access to therapy metrics
• Miniaturized Design: Compact probe form-factor prioritizing comfort and independent home use

Market Position and Certifications

Amazing Gut holds an emerging position in the global home pelvic floor biofeedback market, competing with Laborie and Medtronic traditional clinic-based systems. Key strengths include:

• Research heritage: Rooted in 15+ years of Western Sydney University gut-brain axis research
• Regulatory compliance: TGA Class 1 medical device listed in Australia (ARTG ID 462026, 6 Sep 2024)
• Design excellence: 2024 Good Design Award winner for Medical Product Design
• Published evidence: Clinical trial (Zhou et al. 2024 PLoS ONE) demonstrating improvements in bowel function and symptoms within 6 weeks
• Cost accessibility: AUD $400 home device versus expensive hospital-tethered diagnostics

Corporate Timeline

2019 — Concept originated from a urogynaecologist's question about home biofeedback access
2024 — Received TGA Class 1 approval (ARTG 462026, 6 Sep 2024); won 2024 Good Design Award; published clinical trial in PLoS ONE
2025 — Founded Amazing Gut as a WSU spin-out in April; licensed IP and launched commercial operations; device trialled at Royal Prince Alfred Hospital
2026 — Named one of four recipients of the NSW Medical Devices Fund round to accelerate product scale-up and clinical trials

Target Markets and Applications

• Home Bowel Therapy: Ins＆Outs for patients with chronic constipation, faecal incontinence and rectal pain seeking discreet home treatment
• Remote Clinical Monitoring: Cloud-based data sharing enabling therapists to track patient progress and refine protocols remotely
• Clinical Validation: Royal Prince Alfred Hospital trials and expansion to private physiotherapy practices for real-world evidence generation

Contact Information

Global Headquarters

Address: Sydney, NSW 2088, Australia
Website: www.amazinggut.today
ABN: 73 639 520 657

Roam Technologies | Portable Oxygen Concentrator and AI Solutions

Wed, 13 May 2026 16:10:37 +0800

Company Profile

Roam Technologies Pty Ltd is an Australia-based developer of portable oxygen therapy devices, headquartered in Carlton, New South Wales, Australia. Founded in 2014 by Shan Shan Wang, the company operates as an independent privately-held entity employing 8 people and having raised approximately $20K in total funding, serving patients with chronic respiratory diseases in Australia and future target markets.

Core Products and Technologies

Portable Oxygen Concentrators

• JUNO iPOC: Ultra-portable, tankless intelligent oxygen concentrator weighing under 2 kg, delivering 1-3 L/min continuous flow at 90% medical-grade oxygen (+/- 3%)<
• AI Optimization Engine: Real-time adaptive algorithms tailoring oxygen delivery to individual breathing patterns
• Miniaturized PSA Architecture: Patented downsized pressure swing adsorption system with compact adsorbent layers

Platform Technology

• Advanced Chemistry Process: Proprietary oxygen generation methodology for high-purity output
• Real-Time Optimization: Machine learning-driven flow adjustment based on patient activity and respiration
• Continuous Flow Delivery: Tankless system replacing traditional oxygen cylinders and pulse-dose devices

Market Position and Certifications

Roam Technologies holds an emerging position in the global portable oxygen concentrator market, competing with Inogen and Philips Respironics. Key strengths include:

• 11+ years of Australian respiratory device research and development heritage
• AI-Enabled Personalization: Adaptive oxygen delivery algorithms for real-world mobility
• Regulatory pathway: Currently in clinical development; designed for future FDA and TGA submission
• Patent portfolio: Granted patent on POC miniaturization and downsizing architecture with miniaturized PSA design

Corporate Timeline

2014 — Founded in Australia by Shan Shan Wang to develop next-generation portable oxygen therapy
2022 — Completed angel financing and advanced JUNO prototype development
2023 — Selected to present JUNO technology at Cicada Innovations Tech23 deep tech showcase
2024 — Secured grant funding and accelerator support for regulatory preparation
2026 — Named one of four recipients of the NSW Medical Devices Fund round (A$7.4 million shared across four companies) to accelerate clinical trials and commercialization

Target Markets and Applications

• Home Oxygen Therapy: JUNO iPOC for COPD and chronic respiratory patients requiring daily supplemental oxygen
• Mobile Ambulatory Care: Lightweight continuous-flow device enabling patient mobility and independence
• Clinical Development: Pre-market trials and regulatory submissions for US and Australian market entry

Contact Information

Global Headquarters

Address: Carlton, New South Wales, Australia
Website: www.roamtech.ai

Disclaimer

Note: The JUNO device is currently in clinical development and has not yet been approved by the FDA, TGA or any regulatory body.

Bayesian Health | Clinical AI Platform and Sepsis Monitoring Solutions

Wed, 13 May 2026 15:57:17 +0800

Company Profile

Bayesian Health, Inc. is a US-based clinical AI company and medical device manufacturer, headquartered in 28 Liberty Street, Suite 633, New York, NY 10014, USA, with research roots in Baltimore, Maryland. Founded in 2016 as a Johns Hopkins University spin-off by Dr. Suchi Saria, the company operates as an independent privately-held entity employing 37 people and having raised $40 million in total funding, serving hospitals and health systems across the United States.

Core Products and Technologies

Clinical Intelligence Platform

• TREWS (Targeted Real-Time Early Warning System): Continuous AI platform that monitors every patient, surfaces those needing attention, and guides clinicians to act within existing EHR workflows
• Sepsis Flagging Device: FDA-cleared module providing pre-suspicion continuous screening for sepsis, detecting deterioration up to 48 hours before clinician suspicion
• Multi-Condition Monitoring: Modular agents addressing respiratory failure, cardiac events, and other leading drivers of in-hospital mortality and length of stay

Platform Architecture

• Massively Multimodal Data Integration: Ingests thousands of clinical inputs from EHR and transforms them into clinically meaningful concepts for patient-specific reasoning
• Mixture-of-Experts Data Model: Multiple specialized models plus a routing layer that learns which expert to trust for each patient, preserving early sensitivity while reducing false alerts
• End-to-End Agentic Workflows: Real-time agents inside the EHR showing why a patient is flagged, guiding next steps, coordinating care bundles, and tracking completion
• Monitoring and Governance: Built-in layer tracking real-world performance, drift, and bias across populations and sites, aligned with FDA oversight best practices

Market Position and Certifications

Bayesian Health holds a pioneering position in the continuous clinical AI monitoring market, competing with Mednition and Epic Systems. Key strengths include:

• 10+ years of peer-reviewed health AI research and development heritage
• Pre-Suspicion Screening: First FDA-cleared AI device that monitors for sepsis before clinician suspicion, creating lead time that changes outcomes
• Regulatory compliance: FDA 510(k) cleared (May 12, 2026), prior FDA Breakthrough Device Designation, validated against ISO standards
• Published evidence: Prospective study in Nature Medicine (2022) spanning 764,707 patient encounters across five hospitals with 2,000+ providers
• Global service network: Deployed at leading academic and community health systems with localized implementation support

Corporate Timeline

2016 — Founded as a Johns Hopkins University spin-off by Dr. Suchi Saria to translate lab research into real-world clinical AI
2018 — Completed accelerator programs and early-stage venture financing
2022 — Published prospective validation study in Nature Medicine demonstrating 18% reduction in sepsis mortality and 5.7-hour lead time
2023 — Recognized by TIME, Forbes and the World Economic Forum for clinical AI innovation
2024 — Raised $25 million Series A led by Andreessen Horowitz with participation from the American Medical Association and MemorialCare Innovation Fund
2026 — Received first-ever FDA 510(k) clearance for continuous AI sepsis monitoring on May 12; positioned for CMS NTAP reimbursement beginning October 2026, pending final decision expected early August 2026

Target Markets and Applications

• Hospital Acute Care: TREWS platform for continuous monitoring of medical-surgical floors, emergency departments, and ICUs
• Sepsis Early Detection: Automated flagging and clinical workflow integration to reduce mortality, organ failure, and length of stay
• Health System Quality Initiatives: Enterprise-wide deployment to hardwire proactive care and reduce preventable harm across multiple conditions

Contact Information

Global Headquarters

Address: 28 Liberty Street, Suite 633, New York, NY 10014, USA
Phone: (408) 205-8035
Email: support@bayesianhealth.com
Website: www.bayesianhealth.com

Research Center

Address: Baltimore, Maryland, USA
Johns Hopkins University Affiliation: Technology originated at the JHU Machine Learning and Healthcare Lab

Sunrise Group | HSAT Manufacturer and Digital Clinic

Wed, 13 May 2026 15:36:01 +0800

Company Profile

Sunrise Group (operating as Sunrise SA) is a Belgium-based sleep health technology company and medical device manufacturer, headquartered in Namur, Belgium, with U.S. operations through its acquired Dreem Health clinic. Founded on June 20, 2015, the company operates as an independent privately-held entity having raised a total of $58 million, serving patients and healthcare providers across 49 U.S. states and select European markets.

Core Products and Technologies

Home Sleep Apnea Testing

• Mandibular Sensor: Ultra-lightweight chin-worn device that measures mandibular jaw movements for at-home obstructive sleep apnea diagnosis
• Companion App: Patient-facing mobile interface guiding multi-night testing and transmitting data to cloud-based analysis platforms

Digital Sleep Clinic

• Dreem Health Platform: Virtual sleep clinic connecting patients to licensed sleep specialists for diagnosis and treatment
• AI Analysis Engine: Proprietary algorithm processing mandibular movement bio-signals to detect sleep-disordered breathing and generate automated reports
• Care Coordination Suite: Insurance-covered telehealth pathway integrating home testing, specialist consultation and personalized therapy selection

Market Position and Certifications

Sunrise Group holds a pioneering position in the home sleep apnea testing and virtual sleep medicine market, competing with ResMed and Nox Medical. Key strengths include:

• 10+ years of European sleep technology research and development heritage
• Mandibular Jaw Movement (MJM) Technology: Direct bio-signal measurement validated against polysomnography in an 848-patient study in France
• Regulatory compliance: FDA 510(k) cleared (2023), CE marked for European distribution
• Payor coverage: In-network with Medicare, UnitedHealthcare, Aetna, Humana, Cigna, Anthem, Blue Cross Blue Shield and Health Net of California
• Global service network: Localized technical support across major markets

Corporate Timeline

2015 — Founded in Belgium to develop AI-powered sleep diagnostic hardware
2023 — Received FDA 510(k) clearance for the mandibular home sleep apnea test
2024 — Acquired Dreem Health, a California-based telemedicine sleep clinic, to build an end-to-end care model
2025 — Raised $29 million in a funding round led by Eurazeo with participation from Amazon's Alexa Fund
2026 — Completed an 848-patient validation study in France; partnered with Humana for nationwide member access
2026 — Established inaugural U.S. Medical Advisory Board with Dr. Atul Malhotra and Dr. Diana Thiara

Target Markets and Applications

• Home Sleep Apnea Testing: Mandibular sensor for at-home obstructive sleep apnea screening and multi-night monitoring
• Virtual Sleep Medicine: Dreem Health telehealth for diagnosis and treatment of insomnia, sleep apnea and restless leg syndrome
• Integrated Care Pathways: Partnerships with insurers and referring providers for covered, end-to-end sleep disorder management

Contact Information

Global Headquarters

Address: Chaussée de Marche 598/02, 5101 Namur, Belgium
Phone: +32 81 26 11 26
Email: hello@hellosunrise.com
Website: www.hellosunrise.com
VAT Number: BE 0632 607 373

U.S. Digital Sleep Clinic

Dreem Health
Website: dreemhealth.com

Biozen | Cuffless BP Monitor & Digital Health Solutions

Wed, 13 May 2026 15:23:54 +0800

Company Profile

Biozen, LLC is a US-based digital health company and medical device manufacturer, headquartered in Oklahoma City, Oklahoma, USA, with research and development in Atlanta, Georgia. Founded in 2010, the company operates as an independent privately-held entity employing approximately 26 people, serving clinicians, healthcare partners and adult patients across the United States.

Core Products & Technologies

Cuffless Blood Pressure Monitoring

• Biozen BP1000: FDA-cleared ultra-compact fingertip blood pressure monitor delivering calibration-free spot measurements for adults ages 22-59
• Companion Mobile App: Visual-guided interface that logs readings and maintains comprehensive measurement history

Platform Technology

• Proprietary Pressure Sensing: Direct arterial occlusion detection through fingertip application
• Photoplethysmography (PPG): Optical blood volume change tracking paired with pressure signals
• Physiologically Informed Algorithms: Oscillometric-method computation without per-user calibration against arm cuffs

Market Position & Certifications

Biozen holds a pioneering position in the cuffless blood pressure monitoring market, competing with Biobeat and Aktiia. Key strengths include:

• 15+ years of biosensor and digital health research and development heritage
• Direct Measurement Principle: Absolute blood pressure measurement from the fingertip without estimation or correlation models
• Regulatory compliance: FDA 510(k) cleared (May 2026), validated against ISO 81060-2:2018 for equivalence to cuff-based references
• Intellectual property: Platform protected by more than 68 granted US and international patents

Corporate Timeline

2010 — Founded as a digital health innovator focused on advanced biosensors
2023 — Completed later-stage venture capital financing to scale commercial operations
2026 — Named finalist in ACC Innovation Pitch Challenge; presented prospective clinical validation data at ACC
2026 — Received FDA 510(k) clearance for BP1000 on May 11; opened early access program for clinicians and partners

Target Markets & Applications

• Home Blood Pressure Monitoring: BP1000 for adults seeking convenient, cuffless spot measurements in home environments
• Primary Care & Cardiology Clinics: Calibration-free clinical-grade readings to improve patient compliance and monitoring frequency
• Future Device Integration: BP Sensor platform licensing for smartphones, wearables and connected health ecosystems

Contact Information

Global Headquarters

Address: 7023 N. Classen Blvd., Oklahoma City, Oklahoma 73116, USA
Phone: +1 405-413-5201
Email: aw@biozen.com
Website: www.biozen.com

Research & Development Center

Address: Atlanta, Georgia, USA

Becton Dickinson | MedTech Manufacturer & Infusion Solutions

Wed, 13 May 2026 14:24:44 +0800

Company Profile

Becton, Dickinson and Company (trading as BD) is a US-based manufacturer of medical devices and medication management systems, headquartered in Franklin Lakes, New Jersey, USA. Founded in 1897, the company operates as an independent publicly traded entity listed on the NYSE: BDX, serving healthcare institutions in over 190 countries with more than 60,000 employees.

Core Products & Technologies

Medical Essentials

• BD Vacutainer: Safety-engineered blood collection systems for specimen integrity
• BD SafetyGlide: Needles with passive safety shields to prevent needlestick injuries
• BD Emerald: Syringes with robust design for general-purpose injection and aspiration

Interventional

• BD CentroVena One: All-in-one central venous catheter insertion system launched in 2026
• Liverty TIPS Stent Graft: Transjugular intrahepatic portosystemic shunt for portal hypertension
• Revello Vascular Covered Stent: Peripheral vascular stent with CE Mark for iliac artery treatment

Connected Care

• BD Alaris Infusion System: Smart pumps with Guardrails suite for medication error reduction
• BD Pyxis Pro: AI-enabled automated dispensing cabinet with RFID and illuminated bins
• BD Incada Platform: Cloud-connected analytics for enterprise medication inventory visibility

Biopharma Systems

• BD Hypak: Prefillable syringes and injectable drug delivery systems for biologics
• BD Neopak: Glass prefillable syringes for sensitive biologic drug formulations

Market Position & Certifications

Becton Dickinson holds a global leadership position in the medical device and infusion therapy market, competing with Medtronic and Stryker. Key strengths include:

• 129+ years of US medtech engineering heritage
• Safety-engineered devices: Passive needlestick prevention and antimicrobial catheter coatings
• Regulatory compliance: CE marked, FDA cleared, ISO 13485 certified globally
• Global service network: Localized technical support across major markets

Corporate Timeline

1897 — Founded in New Jersey by Maxwell Becton and Fairleigh Dickinson
2015 — Expanded infusion and medication management capabilities via CareFusion acquisition
2017 — Entered interventional medicine through C. R. Bard acquisition
2022 — Spun off Diabetes Care business into Embecta Corporation
2026 — Completed separation of Biosciences & Diagnostic Solutions to Waters, becoming pure-play medtech; launched CentroVena One in the U.S.

Target Markets & Applications

• Hospital Acute Care: Alaris infusion and Pyxis medication management systems
• Operating Rooms & Interventional Suites: Surgical, vascular and urology devices
• Pharmaceutical Manufacturing: Prefillable syringes and biologic drug delivery platforms
• Clinical Laboratories: Specimen collection and safety-engineered sharps disposal

Contact Information

Global Headquarters

Address: 1 Becton Drive, Franklin Lakes, New Jersey 07417, USA
Phone: +1 201.847.6800
Website: www.bd.com

Investor Relations

Stock: NYSE: BDX
Website: investors.bd.com

Nanjing Panshida | Electrolyte Analyzer & Reagent Maker

Tue, 12 May 2026 08:56:29 +0800

Company Profile

Nanjing Panshida Electronic Instrument Co., Ltd. (trading as Panstar) is a China-based manufacturer of clinical electrolyte analyzers and ISE reagents, headquartered in Nanjing, Jiangsu, China. Founded on August 21, 1997, the company operates as an independent privately-held entity with a registered capital of RMB 12 million, serving hospitals and clinical laboratories in over 20 countries.

Core Products & Technologies

Electrolyte Analyzers

• AES Series: High-throughput automated analyzer with dual-channel ISE measurement for K+, Na+, Cl-, Ca2+, Li+, pH and TCO2
• PSD-15A / PSD-15B: Semi-automatic and automatic ISE analyzers measuring K+, Na+, Cl-, Ca2+, pH with 40 s test time
• PSD-16A / PSD-16B: Dual-channel systems with ISE plus gas-sensitive sensor for TCO2, 60 s test time
• FT-320 / FT-330: Compact automated analyzers with 5.7-inch touchscreen and integrated reagent packs

Reagents & Electrodes

• ISE Calibration Solutions: Precision calibrators for drift correction and slope measurement
• TCO2 Reagents: Dedicated reagents for total carbon dioxide analysis
• Ion-Selective Electrodes: Replaceable electrodes for K, Na, Cl, Ca, Li, Mg, pH, TCO2 and Ref

Market Position & Certifications

Nanjing Panshida holds a specialist position in the global clinical electrolyte analysis market, competing with Mindray and Roche Diagnostics. Key strengths include:

• 28+ years of Chinese IVD engineering heritage
• Ion-Selective Electrode (ISE) Technology: Direct measurement method with manual and auto-sampling
• Regulatory compliance: CE marked, NMPA registered (China), ISO 13485 and ISO 9001 certified
• Global service network: Localized technical support across major markets

Corporate Timeline

1997 — Founded in Nanjing as a clinical electrolyte analyzer manufacturer
2016 — Filed trademark application for ＂PANSTAR INSTRUMENT＂ in Class 10 medical devices
2017 — Increased registered capital to RMB 12 million; relocated to Qingshuiting East Road headquarters
2017 — Granted utility model patents for turntable device and electrolyte analyzer components

Target Markets & Applications

• Hospital Clinical Labs: AES and PSD series for high-throughput electrolyte testing
• Emergency & ICU Departments: Rapid whole blood electrolyte analysis for critical care
• Primary Care & POCT: Compact FT series for decentralized diagnostic settings

Contact Information

Global Headquarters

Address: 2/F, Building 1, No. 992 Qingshuiting East Road, Molin Street, Jiangning District, Nanjing, Jiangsu, China
Phone: +86 25-84647543
Email: 911937247@qq.com
Website: www.panstarinst.com
Unified Social Credit Code: 91320115249979971F

INT Medical | Cardiac Catheters & Interventional Devices Manufacturer

Tue, 12 May 2026 02:26:22 +0800

Company Profile

Shanghai INT Medical Instruments Co., Ltd. is a China-based manufacturer of interventional cardiovascular and peripheral vascular devices, headquartered in Jiading District, Shanghai, China. Founded in June 2006 and listed on the Hong Kong Stock Exchange Main Board (HKEX: 01501) in 2019, the company operates as an independent publicly traded entity with KDL Holdings as its major shareholder, serving hospital catheterization labs and distributors across over 90 countries and regions. The group encompasses 24 subsidiaries spanning cardiology, peripheral vascular, neurovascular, electrophysiology, and structural heart.

Core Products & Technologies

Cardiac Interventional Devices

• Balloon Inflation Devices: High-pressure balloon pumps for PCI procedures with digital and analog gauge options
• Introducer Sheath Kits: Femoral and radial access sheaths with integrated hemostasis valves for catheter insertion
• Angiographic Guidewires: Hydrophilic and standard coating guidewires for coronary and peripheral vessel navigation
• Coronary Scoring Balloon Catheters: Nylon-cut scoring balloon for lesion preparation in calcified and fibrotic stenoses
• Guiding Catheters: Backup support catheters for complex coronary interventions

Peripheral & Neurovascular Systems

• Microcatheters & Microguidewires: Neurovascular and peripheral micro-systems for embolization and contrast injection
• Support Catheters: Distal access and aspiration catheters for thrombus removal and device delivery
• Balloon Guiding Catheters: Large-lumen catheters combining guide and balloon functionality for stroke interventions

Multi-Division Portfolio

• Electrophysiology: Diagnostic and ablation accessories for arrhythmia management
• Structural Heart: Transcatheter delivery accessories and occluder systems
• Urology & ENT: Interventional consumables for minimally invasive surgical specialties

Market Position & Certifications

INT Medical holds a leading domestic position in China's cardiac interventional accessory market, competing with MicroPort Scientific Corporation and Lepu Medical Technology. Key strengths include:

• 18+ years of interventional device engineering heritage with full vertical integration from mold design to ethylene oxide sterilization
• Regulatory compliance: ISO 13485, CE marked (43 product categories), and FDA registered (26 products)
• Intellectual property: 734 granted patents and 42 software copyrights as of 2025
• Enterprise honors: National Specialized and Innovative "Little Giant" SME, National IP Advantage Enterprise, Shanghai Enterprise Technology Center, Shanghai Innovative Enterprise Headquarters
• Sustainability recognition: Selected for S&P Global Sustainability Yearbook (China Edition) for two consecutive years (2024–2025)

Corporate Timeline

2006 — Founded in Shanghai as an interventional device manufacturer
2015 — Rebranded to Shanghai KDL Medical Devices Co., Ltd.
2019 — Listed on Hong Kong Stock Exchange Main Board (01501.HK)
2023 — Rebranded to Shanghai INT Medical Instruments Co., Ltd. (瑛泰医疗)
2024 — Coronary scoring balloon catheter approved by NMPA; selected for S&P Global Sustainability Yearbook
2025 — Acquired majority stake in Hangzhou Weiqiang Medical Technology; hydrophilic-coated guidewire approved; added 5 NMPA Class III and 14 Class II registrations; full-year revenue exceeded RMB 1 billion
2026 — January: Completed placement of shares to strengthen working capital and R&D capacity. April: Proposed abolition of supervisory board and revision of articles of association. May: Annual general meeting scheduled for May 28

Target Markets & Applications

• Coronary Interventions: PCI accessory devices for balloon angioplasty, stent delivery, and lesion preparation in cardiology departments
• Neurovascular Therapy: Microcatheters and guidewires for stroke intervention and aneurysm embolization
• Peripheral Vascular Disease: Access sheaths and guidewires for lower-extremity and renal artery procedures
• Structural Heart Procedures: Delivery system components for TAVR and left-atrial appendage closure
• Global OEM & Distribution: Private-label manufacturing and component supply for international medical device brands

Contact Information

Global Headquarters

Address: Building 2, No. 925 Jinyuan Yi Road, Jiading District, Shanghai, China
Tel: +86-21-3997****
Website: int-medical.com

Hong Kong Office

Address: Suite 3101, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Stock: HKEX: 01501.HK

Investor Relations

Major Shareholder: KDL Holdings
Website: hkexnews.hk
Email: ir@int-medical.com

CoreTissue BioEngineering | Decellularized Ligament & ACL Solutions

Tue, 12 May 2026 01:40:04 +0800

Company Profile

CoreTissue BioEngineering Inc. is a Japan-based medtech startup developing tissue-regenerative ligaments for anterior cruciate ligament (ACL) reconstruction, headquartered in Yokohama, Kanagawa, Japan. Founded in November 2016 as a spin-out from Waseda University, the company operates as an independent private entity led by CEO Yoji Jokura, Ph.D. and founder Kiyotaka Iwasaki, Ph.D., serving orthopedic surgeons and sports medicine centers in Japan and the United States. The company maintains a US office in Palo Alto, California.

Core Products & Technologies

Tissue-Regenerative Ligament System

• CT-ACL001 Tissue-Regenerative Ligament: Implantable decellularized bovine tendon graft for ACL reconstruction, designed to achieve strength comparable to human tendon and ligament-level thickness while eliminating cellular components that trigger immune or inflammatory responses
• Microwave Decellularization Technology: Proprietary process using microwaves to vibrate water molecules, enabling cell-membrane dissolving solutions to penetrate deep into thick tendon tissue without damaging collagen structure — the first in the world to achieve this for ligament-scale tissue

Manufacturing & Development Pipeline

• Mass-Production Equipment: Verification unit under joint development with Microwave Chemical Co., Ltd. to scale up microwave-based decellularization for commercial production targeted for 2028
• Clinical Trial Infrastructure: Company-sponsored investigator-initiated trial network spanning six top-tier Japanese university hospitals

Market Position & Certifications

CoreTissue BioEngineering holds a pioneering position in the decellularized biological ligament segment, competing with Neoligaments (Cousin Biotech) and Shanghai Pine ＆ Power Biotech in the global artificial ligament market. Key strengths include:

• World-first microwave decellularization: Unique ability to process thick tendon tissue while preserving mechanical strength and collagen architecture
• Regulatory milestones: Class I medical device manufacturing and marketing license obtained in Japan (July 2023); FDA Pre-Submission completed (2020); product not yet approved in any country pending pivotal trial completion
• Clinical validation: First-in-human treatment performed in December 2024; safety cohort completed and randomized controlled cohort initiated in May 2026
• Government support: Research and clinical trials funded by Japan Agency for Medical Research and Development (AMED) and NEDO Deep-Tech Startups Support Program (JPY 494 million, 2025–2027)

Corporate Timeline

2016 — Founded as a Waseda University spin-out in Yokohama to commercialize decellularized tissue ligaments
2019 — Received first investment from Waseda University Official Fund; granted Ogasawara Foundation research funding
2020 — Adopted to AMED's 5th CiCLE grant program; completed FDA Pre-Submission meeting
2021 — Elected to J-Startup national support program; obtained highly controlled medical device manufacturing and marketing authorization in Japan; raised JST SUCCESS program funding
2022 — Obtained medical device manufacturing license; featured on NHK WORLD "Medical Frontiers"; selected for Yokohama City US Life Science Market Development Support Program
2023 — Completed Series A funding of approximately JPY 560 million; obtained Class I medical device license in Japan; selected for AMED Advanced Medical Devices and Systems Development Project
2024 — First patient treated with CT-ACL001 regenerative ligament in December; selected as coworking member of Japan Innovation Campus in Silicon Valley; accepted into accelerator backed by Mitsubishi Corporation (Americas) and Fogarty Innovation
2025 — Raised approximately JPY 600 million from Nippon Ham and Mitsui Sumitomo Insurance Venture Capital; commenced mass-production equipment development with Microwave Chemical; selected for 8th NEDO-DTSU Support Project
2026 — January: Began developing mass-production equipment with Microwave Chemical. May: Safety cohort completed; randomized controlled cohort initiated across six Japanese university hospitals; initial results presented at ESSKA Congress

Target Markets & Applications

• ACL Reconstruction Surgery: Primary ligament graft for patients requiring anterior cruciate ligament repair, offering an alternative to autologous hamstring tendon harvest
• Sports Medicine: Treatment for athletes with ACL injuries to enable early return to competition and restore peak performance
• Revision ACL Surgery: Graft option for re-rupture cases where insufficient autologous tendon remains for reconstruction
• Future Orthopedic Expansion: Potential application to other ligament injuries and rotator cuff reconstruction under exploratory development

Contact Information

Global Headquarters

Address: Life Science Research Center 301, Suehirocho 1-1-43, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: +81-45-642-5455
Email: info@coretissue.com
Website: coretissue.com

US Office

Address: Japan Innovation Campus, 212 Homer Avenue, Palo Alto, CA 94301, USA

Corporate Structure

CoreTissue BioEngineering Inc. operates as an independent private company with no publicly traded parent company.
CEO: Yoji Jokura, Ph.D.
Founder: Kiyotaka Iwasaki, Ph.D.
Key Investors: WERU Investment (Waseda University affiliated), Nippon Ham, Mitsui Sumitomo Insurance Venture Capital
Investor Relations: Not applicable — privately held startup with no publicly traded stock.

Envoy Medical | Fully Implanted Hearing Implant & Cochlear Solutions

Tue, 12 May 2026 01:28:49 +0800

Company Profile

Envoy Medical, Inc. is a US-based manufacturer of fully implanted hearing devices, headquartered in White Bear Lake, Minnesota, USA. Founded in 2006 (predecessor research dating to 1995), the company operates as an independent publicly traded entity listed on NASDAQ: COCH, serving otology and audiology centers across the United States and Europe. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and quality of life.

Core Products & Technologies

Fully Implanted Active Middle Ear Implant

• Esteem FI-AMEI: The only FDA-approved, fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, offering 24/7 hearing using the ear's natural anatomy without externally worn components or ear canal insertion; commercially available in the US since 2010

Investigational Fully Implanted Cochlear Implant

• Acclaim Cochlear Implant: First-of-its-kind fully implanted cochlear implant designed for severe to profound sensorineural hearing loss, leveraging a proprietary piezoelectric sensor that uses the ear's natural anatomy to capture sound instead of an external microphone; no visible hardware, no external processor, and no magnets
• Rechargeable Battery System: Large-capacity internal battery providing approximately five days of use between recharges, with replacement required roughly once every 10 years
• MRI Compatibility: Designed to be MRI compatible without magnet-related restrictions

Digital & Clinical Ecosystem

• Esteem Personal Programmer: External activation and programming device for initial setup; not required for daily use once activated
• Clinical Trial Network: Seven top-tier cochlear implant centers across the US conducting the pivotal Acclaim trial

Market Position & Certifications

Envoy Medical holds a pioneering position as the only company with an FDA-approved fully implanted hearing device and a fully implanted cochlear implant in pivotal trials, competing with Cochlear Ltd. and Advanced Bionics (Sonova) in the broader implantable hearing market. Key strengths include:

• 15+ years of fully implanted hearing device commercial heritage with the Esteem platform
• Sensor technology leadership: Proprietary implanted piezoelectric sensor validated as the "gold standard" for fully implanted hearing implants
• Regulatory milestones: Esteem FDA approved (2010); Acclaim FDA Breakthrough Device Designation (2019) and IDE approval (2024)
• Intellectual property: 47 patents across North America, Europe, Asia, and Australia as of February 2026, including US Patent No. 12,544,564 for cochlear implant signal processing and Hong Kong patents for combination hearing aid/cochlear implant systems
• Clinical validation: Over 900 Esteem implants worldwide; Acclaim pivotal trial fully enrolled with 56 participants as of March 2026, all patients through activation as of April 2026

Corporate Timeline

1995 — Predecessor research begins on fully implanted hearing sensor technology
2001 — First in-human feasibility study conducted
2004 — European clinical trials initiated for Esteem
2006 — Company rebranded to Envoy Medical; CE Mark obtained for Esteem
2010 — Esteem receives FDA approval, becoming the first fully implanted hearing device available in the US
2019 — Acclaim cochlear implant granted FDA Breakthrough Device Designation
2022 — Acclaim receives Investigational Device Exemption (IDE) for feasibility study
2024 — FDA approves IDE for Acclaim pivotal trial; trial sites selected
2025 — Pivotal trial enrollment begins; first 10-patient data submitted to FDA enabling trial expansion; extinguished over USD 32 million in debt; Nasdaq grants continued listing extension to February 23, 2026
2026 — February: Closed upsized USD 78 million public offering led by Nantahala Capital; global IP portfolio expanded to 47 patents. March: Pivotal trial fully enrolled (56 patients). April: All 56 patients through activation; first three patients complete 12-month endpoint; Chas McKhann appointed to board; anticipated PMA submission to FDA in Q2 2027

Target Markets & Applications

• Moderate to Severe Sensorineural Hearing Loss: Esteem FI-AMEI for adults seeking invisible, 24/7 hearing without daily device management
• Severe to Profound Sensorineural Hearing Loss: Acclaim cochlear implant for adults who are candidates for cochlear implantation but prefer a fully internal, discreet solution
• Otolaryngology ＆ Neurotology Practices: Surgical implantation and long-term follow-up care at specialized ENT centers
• Patient Populations Stigmatized by External Devices: Individuals avoiding traditional cochlear implants due to visible external processors and social stigma

Contact Information

Global Headquarters

Address: 4875 White Bear Parkway, White Bear Lake, MN 55110, USA
Tel: +1-877-900-3277
Website: envoymedical.com

Investor Relations

Stock: NASDAQ: COCH
Website: ir.envoymedical.com
Email: Envoy@kcsa.com (add COCH in subject line for distribution list)